Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients
Open Access
- 10 March 2020
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 38 (5) , 1463-1471
Abstract
Summary: Cisplatin is a widely used chemotherapy for the treatment of certain solid tumors. Ototoxicity and subsequent permanent hearing loss remain a serious dose-limiting side effect associated with cisplatin treatment. To date, no therapies have been approved to prevent or treat cisplatin-induced hearing loss (CIHL). Sodium thiosulfate effectively inactivates cisplatin through covalent binding and may provide protection against cisplatin-induced ototoxicity. DB-020 is being developed as a novel formulation of sodium thiosulfate pentahydrate in 1% sodium hyaluronate for intratympanic injection (IT), enabling the delivery of high concentrations of thiosulfate into the cochlea prior to cisplatin administration. In the DB-020-002 phase 1a single-ascending dose study, healthy volunteers were enrolled into 5 cohorts to receive different doses of DB-020 via IT injection. Cohorts 1–4 received unilateral injections while Cohort 5 received bilateral injections. Plasma thiosulfate pharmacokinetics was measured, and safety and audiometric data were collected throughout the study. This study has demonstrated that intratympanic administration of DB-020 results in nominal systemic increases in thiosulfate levels, hence it should not compromise cisplatin anti-tumor efficacy. Furthermore, DB-020 was safe and well tolerated with most adverse events reported as transient, of mild-to-moderate severity and related to the IT administration procedure. These results support the design and execution of the ongoing proof-of-concept study, DB-020-002, to assess otoprotection using DB-020 in cancer patients receiving cisplatin without negatively impacting cisplatin anti-tumor efficacy.Keywords
This publication has 18 references indexed in Scilit:
- Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection StrategiesToxics, 2015
- Sodium Thiosulfate Pharmacokinetics in Hemodialysis Patients and Healthy VolunteersClinical Journal of the American Society of Nephrology, 2011
- Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig modelCancer Chemotherapy and Pharmacology, 2011
- Immunohistochemical detection of platinated DNA in the cochlea of cisplatin-treated guinea pigsHearing Research, 2005
- Intratympanic gentamicin for unilateral Meniere's disease: results of therapyClinical Otolaryngology, 2003
- The Hearing Handicap Inventory for AdultsEar & Hearing, 1990
- Ototoxicity of low- and moderate-dose cisplatinCancer, 1985
- 2-ROUTE CHEMOTHERAPY USING HIGH-DOSE IP CISPLATIN AND IV SODIUM THIOSULFATE, ITS ANTIDOTE, FOR PERITONEALLY DISSEMINATED CANCER IN MICE1984
- Stimulated acoustic emissions from within the human auditory systemThe Journal of the Acoustical Society of America, 1978
- Preferred Method For Clinical Determination Of Pure-Tone ThresholdsJournal of Speech and Hearing Disorders, 1959